Treatment of Metastatic Triple-Negative Breast Cancer
The Pharma Data
MARCH 25, 2021
SG contains a genotoxic component and can cause teratogenicity and/or embryo-fetal lethality when administered to a pregnant woman. In addition to the European Union, regulatory reviews of SG in metastatic TNBC are currently underway in the U.K., Embryo-Fetal Toxicity.
Let's personalize your content